Evidence map›Paper›PMID 25211663›Full record

Trial reportBritish journal of cancer2014

HER2/neu testing in primary colorectal carcinoma.

B Ingold Heppner, H-M Behrens, K Balschun, J Haag, S Krüger, T Becker, C Röcken

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 86 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
86citing papers in PubMed, 3 pooled it
4.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

86 citing papers in PubMed, 3 syntheses or guidelines pooled it, 167 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Trial
  5. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015
    Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. HER2-Positive Metastatic Colorectal Cancer.Current treatment options in oncology · 2024
    Review
  20. Review

26 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

B Ingold HeppnerDepartment of Pathology, Campus Mitte, Charité University Hospital, 10117 Berlin, Germany.
H-M BehrensDepartment of Pathology, Christian-Albrechts-University, 24105 Kiel, Germany.
K BalschunDepartment of Pathology, Christian-Albrechts-University, 24105 Kiel, Germany.
J HaagDepartment of Pathology, Christian-Albrechts-University, 24105 Kiel, Germany.
S KrügerDepartment of Pathology, Christian-Albrechts-University, 24105 Kiel, Germany.
T BeckerDepartment of General Surgery and Thoracic Surgery, Christian-Albrechts-University, 24105 Kiel, Germany.
C RöckenDepartment of Pathology, Christian-Albrechts-University, 24105 Kiel, Germany.
Kiel University · DECharité - Universitätsmedizin Berlin · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnti-HER2/neu therapy is well-established in breast and gastric carcinoma. The increased understanding of this pathway led to the identification of new promising drugs in addition to trastuzumab, offering further perspectives. The role of HER2/neu in colorectal carcinoma is controversially discussed, as discrepant data has been reported.

methodsHere, we retrospectively assessed the prevalence of HER2/neu positivity in a large series of colorectal carcinoma, testing HER2/neu status according to current recommendations. We correlated the results to clinico-pathological data and patient survival.

resultsOverall, in 1645 primary colorectal carcinoma cases, 1.6% of the cases were HER2/neu positive. HER2/neu positivity significantly correlated with higher UICC stages (P=0.017) and lymph node metastases (P=0.029). In the subgroup of sigmoideal and rectal carcinomas, positive HER2/neu status was associated with T-category (P=0.041) and higher UICC stages (P=0.022). Although statistically not significant, HER2/neu-positive colorectal carcinomas displayed a tendency to poorer overall survival.

conclusionsThese results illustrate the importance of testing HER2/neu by approved diagnostic techniques and scoring systems. We assume that although the prevalence of HER2/neu positivity in colorectal carcinoma is low, HER2/neu testing in advanced, nodal-positive colorectal carcinoma is reasonable, offering a potential target in high risk colorectal carcinoma.

Indexed as

AdolescentAdultAgedAged, 80 and overBiomarkers, TumorColorectal NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLymphatic MetastasisMaleMiddle AgedNeoplasm StagingPrognosisBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID25211663
PMCPMC4229629
OpenAlexW2046073869

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.